Copyright
©The Author(s) 2020.
World J Clin Cases. Oct 6, 2020; 8(19): 4303-4310
Published online Oct 6, 2020. doi: 10.12998/wjcc.v8.i19.4303
Published online Oct 6, 2020. doi: 10.12998/wjcc.v8.i19.4303
Ref. | Object | Group 1 | Group 2 | P value |
Jin et al[8] | GI symptoms | Without GI symptoms | ||
Incidence of liver injury | 17.57% | 8.84% | 0.035 | |
Rate of chronic liver disease | 10.81% | 2.95% | 0.004 | |
Incidence of the severe and critical types | 22.97% | 8.14% | < 0.001 | |
Yao et al[10] | Critical type patients (%) | Liver injury group (77.3%) | Non-liver injury group (27.8%) | 0.002 |
Wan et al[14] | Mild cases | Severe cases | ||
Aspartate aminotransferase, U/L (≤ 40) | 84% | 62.5% | 0.0005 | |
Lactate dehydrogenase, U/L (> 250) | 29% | 75% | 0.0055 |
- Citation: Zhao JN, Fan Y, Wu SD. Liver injury in COVID-19: A minireview. World J Clin Cases 2020; 8(19): 4303-4310
- URL: https://www.wjgnet.com/2307-8960/full/v8/i19/4303.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i19.4303